New research deepened depression biology and aimed at more scalable screening approaches. Scientists reported a stress-triggered molecular switch that drives depression, adding a mechanistic lead for how chronic stress translates into loss of motivation and low mood. On the clinical detection side, a hybrid speech-model screening study reported performance at 95% accuracy for depression screening, reflecting a push to reduce reliance on time-intensive clinical interviews. Together, these findings connect mechanistic insight with detection innovation—potentially enabling earlier identification and more targeted interventions once the biological pathway is better validated. For the market, CNS development remains high-risk, but the dual focus on “why” and “how to measure” reinforces ongoing efforts to modernize both therapy discovery and access to diagnosis.